Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
David VenetMattia ReditiMarion MaetensDebora FumagalliDavid N BrownSamira MajjajRoberto SalgadoLajos PusztaiNadia HarbeckSarra El-AbedYingbo WangCristina SauraHenry L GómezVladimir Fedorovich SemiglazovEvandro de AzambujaJens HuoberPaolo G NuciforoSerena Di CosimoMartine PiccartSherene LoiFrançoise RothéChristos SotiriouPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Our analysis identified ERBB2 copy number as well as 6q23-24 CNAs as predictors of response to anti-HER2-based treatment. ERBB2 expression outperformed ERBB2 amplification. The complexity of the 6q23-24 region warrants further investigation.